Eledon reports Q3 net loss $17.5M; Phase 2 BESTOW positive; raises $57.5M

Eledon Pharmaceuticals, Inc.

Net loss $17.5M ($0.21/shr) vs net income $77M (incl $96.4M warrant gain) in Q3 2024.
Cash & investments $93.4M at Sep 30, down from $140.2M at Dec 31, 2024.
Phase 2 BESTOW: tegoprubart showed favorable safety, eGFR ~69 at 12 months; plans Phase 3 in 2026.
Completed $57.5M public offering on Nov 13, net proceeds ~$53.6M to advance transplant programs.
Anticipates FDA guidance on Phase 3 trial design for kidney transplantation in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.